• PolyPid will host a virtual Investor Day on October 28, 2026, at 11:30 a.m. ET.
• Management will outline its “PolyPid 2030” long-term growth and pipeline strategy.
• An update will cover D-PLEX₁₀₀ for colorectal surgical infection prevention, under FDA priority review with a November 28, 2026, decision target.
• Management will introduce PD01B, a diabetic foot infection treatment candidate based on Kynatrix delivery technology.
• Warren S. Joseph will discuss diabetic foot infections, treatment limitations and the potential role of locally delivered, controlled-release antibiotics.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PolyPid Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610150830PRIMZONEFULLFEED9845600) on October 15, 2026, and is solely responsible for the information contained therein.